@prefix : <http://www.transceleratebiopharmainc.com/LY246708/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix bc: <http://www.assero.co.uk/BiomedicalConcept#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/LY246708/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#711d0a71-ff16-4746-ad38-22fa699ac1f2>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#933bf28b-c3b2-45c5-998a-a9308126af12>
	rdf:type pr:Epoch ;
	isoC:label "Treatment"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#8c1adef5-87dc-4d37-b10e-13380206176a>
	rdf:type pr:Arm ;
	isoC:label "High Dose"^^xsd:string ;
	pr:description "High Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#69d1df13-b520-413f-9fc3-d0670e8440b7>
	rdf:type pr:Arm ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:description "Low Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#d2a623f1-8151-486a-b67f-9ee907fd852b>
	rdf:type pr:Arm ;
	isoC:label "Placebo"^^xsd:string ;
	pr:description "Placebo"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#2eb7cfb2-595c-4a73-becb-0d21f6b30df8>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#8c1adef5-87dc-4d37-b10e-13380206176a> ;
	pr:inEpoch <http://www.assero.co.uk/EP#711d0a71-ff16-4746-ad38-22fa699ac1f2> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#217a5c00-fa5d-460d-8b10-946c3b0062d1> ;
.
<http://www.assero.co.uk/ELE#9f5d0206-9760-4aaa-9591-c52b3f9c222a>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#69d1df13-b520-413f-9fc3-d0670e8440b7> ;
	pr:inEpoch <http://www.assero.co.uk/EP#711d0a71-ff16-4746-ad38-22fa699ac1f2> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#217a5c00-fa5d-460d-8b10-946c3b0062d1> ;
.
<http://www.assero.co.uk/ELE#ca200e79-bab3-4858-8053-bfc2c25c1e22>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#d2a623f1-8151-486a-b67f-9ee907fd852b> ;
	pr:inEpoch <http://www.assero.co.uk/EP#711d0a71-ff16-4746-ad38-22fa699ac1f2> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#217a5c00-fa5d-460d-8b10-946c3b0062d1> ;
.
<http://www.assero.co.uk/ELE#4b238df6-4b30-41e0-b7d8-daa1eff4f2a2>
	rdf:type pr:Element ;
	isoC:label "High Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#8c1adef5-87dc-4d37-b10e-13380206176a> ;
	pr:inEpoch <http://www.assero.co.uk/EP#933bf28b-c3b2-45c5-998a-a9308126af12> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#c9d5b580-df6b-4c96-88f1-eb1d6f24cd38> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3f1f5c25-8f4f-485a-8fe7-e8abd68e31a6> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#1b3d6e57-b5c6-4459-b431-45c5833e8cdf> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#8b5804ee-420b-49d5-aee1-8b9423293788> ;
.
<http://www.assero.co.uk/ELE#5e31cebe-4dc9-48b5-ac14-03fdec3ec0f6>
	rdf:type pr:Element ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#69d1df13-b520-413f-9fc3-d0670e8440b7> ;
	pr:inEpoch <http://www.assero.co.uk/EP#933bf28b-c3b2-45c5-998a-a9308126af12> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#c9d5b580-df6b-4c96-88f1-eb1d6f24cd38> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3f1f5c25-8f4f-485a-8fe7-e8abd68e31a6> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#1b3d6e57-b5c6-4459-b431-45c5833e8cdf> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#8b5804ee-420b-49d5-aee1-8b9423293788> ;
.
<http://www.assero.co.uk/ELE#ef4cf275-a0e5-4d95-8869-7f3b918b534d>
	rdf:type pr:Element ;
	isoC:label "Placebo"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#d2a623f1-8151-486a-b67f-9ee907fd852b> ;
	pr:inEpoch <http://www.assero.co.uk/EP#933bf28b-c3b2-45c5-998a-a9308126af12> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#c9d5b580-df6b-4c96-88f1-eb1d6f24cd38> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3f1f5c25-8f4f-485a-8fe7-e8abd68e31a6> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#1b3d6e57-b5c6-4459-b431-45c5833e8cdf> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#8b5804ee-420b-49d5-aee1-8b9423293788> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "LY246708"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:21+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "H2Q-MC-LZZT"^^xsd:string ;
	pr:title "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease."^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#8c1adef5-87dc-4d37-b10e-13380206176a> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#69d1df13-b520-413f-9fc3-d0670e8440b7> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#d2a623f1-8151-486a-b67f-9ee907fd852b> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#711d0a71-ff16-4746-ad38-22fa699ac1f2> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#933bf28b-c3b2-45c5-998a-a9308126af12> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#9c12cdc5-2c96-439b-b30f-e09daa2aa6dc> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#702c50ff-d03c-4253-86c0-21fdf3ea52fe> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#2b86b1fc-5461-48cf-bf92-f6b6a27e0b48> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#1cec1d43-0835-4308-9b4c-3db1e4c3a6de> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "LY246708"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15601> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66735/V4#C66735_C15228> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "DS8500-A-U202"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:21+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_DIA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_M/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "DS8500-A-U202"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:21+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_RA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_I/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C16084> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "FLU 001"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:21+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_INF/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_V/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "FLU001"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15602> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-Alzheimers-BWE_V003"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:21+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT_TALib-ALZ-BWE_V003"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C49686> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98722> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS>
	rdf:type bc:Assessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T11:07:20+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "ASS DAD"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105183/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105181/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105171/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105204/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "5"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105199/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "6"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105173/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "7"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105202/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "8"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105203/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "9"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105172/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "10"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105185/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "11"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105178/V1#BCI> ;
.
<http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "BL"^^xsd:string ;
.
<http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123>
	rdf:type pr:Visit ;
	isoC:label "Week 8"^^xsd:string ;
	pr:shortName "Wk8"^^xsd:string ;
.
<http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e>
	rdf:type pr:Visit ;
	isoC:label "Week 12"^^xsd:string ;
	pr:shortName "Wk12"^^xsd:string ;
.
<http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83>
	rdf:type pr:Visit ;
	isoC:label "Week 16"^^xsd:string ;
	pr:shortName "Wk16"^^xsd:string ;
.
<http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292>
	rdf:type pr:Visit ;
	isoC:label "Week 24"^^xsd:string ;
	pr:shortName "Wk24"^^xsd:string ;
.
<http://www.assero.co.uk/TP#217a5c00-fa5d-460d-8b10-946c3b0062d1>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#9521059a-72de-4495-9417-8047248ce6f2> ;
	pr:inVisit <http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#92589d31-6e92-4331-be63-96b8b7b8c7db> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#f9a08469-2804-4ecd-a7f8-07a7cca1ada3> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#ccc6be6a-0346-4ea4-a82f-9e30fc9f996a> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#6eafcf3a-2d16-4ab3-b3bc-1c55f60ff9b3> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#563ba7f6-f119-45e9-a63f-042223102765> ;
.
<http://www.assero.co.uk/TP#c9d5b580-df6b-4c96-88f1-eb1d6f24cd38>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#ae8b6b4b-c9a0-4483-b186-0894c38fd9e3> ;
	pr:inVisit <http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#4e32d2e9-b8a4-4ab2-acb7-eb06cbb687d9> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#4e18dc0a-1a4d-4dff-842c-f3a88badcb57> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#a13340e0-2c41-48f4-b3ff-45d649fc896a> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#fe8fc631-1b01-439e-91c9-c671926e9fd9> ;
.
<http://www.assero.co.uk/TP#3f1f5c25-8f4f-485a-8fe7-e8abd68e31a6>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#744f60d8-0760-42fb-b813-69a139b77c11> ;
	pr:inVisit <http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#20dc755b-7130-48e3-9aee-f8865f2fc010> ;
.
<http://www.assero.co.uk/TP#1b3d6e57-b5c6-4459-b431-45c5833e8cdf>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#755a9429-fa03-468e-9389-ecbd52fe8edb> ;
	pr:inVisit <http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#56336c99-3c13-44d7-a17a-c62b35ca0ee8> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#81419f1a-ac1c-41a3-b37f-382f703f3492> ;
.
<http://www.assero.co.uk/TP#8b5804ee-420b-49d5-aee1-8b9423293788>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#acfd60c4-b519-4b20-bd70-4606f9ece1b4> ;
	pr:inVisit <http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#68542f4f-68e4-4f01-a8d9-df94b88095a1> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#b1d43f19-841f-43a9-8b90-a63d5d1963dd> ;
.
<http://www.assero.co.uk/IC#9521059a-72de-4495-9417-8047248ce6f2>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "0"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#ae8b6b4b-c9a0-4483-b186-0894c38fd9e3>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4838400"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#744f60d8-0760-42fb-b813-69a139b77c11>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "7257600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#755a9429-fa03-468e-9389-ecbd52fe8edb>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "9676800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#acfd60c4-b519-4b20-bd70-4606f9ece1b4>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "14515200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#9c12cdc5-2c96-439b-b30f-e09daa2aa6dc>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimer’s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_1/V1#OB> ;
.
<http://www.assero.co.uk/IC#702c50ff-d03c-4253-86c0-21fdf3ea52fe>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_3/V1#OB> ;
.
<http://www.assero.co.uk/IC#2b86b1fc-5461-48cf-bf92-f6b6a27e0b48>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_4/V1#OB> ;
.
<http://www.assero.co.uk/IC#1cec1d43-0835-4308-9b4c-3db1e4c3a6de>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimer’s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_5/V1#OB> ;
.
<http://www.assero.co.uk/IC#d5dcef7c-91cc-4f31-8b3b-bb5dbc8e0971>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_6/V1#OB> ;
.
<http://www.assero.co.uk/IC#993f6b7c-4836-469d-9c53-d601d52afc00>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimer’s Disease Assessment Scale – Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#c1f5473f-c74b-4a45-a883-841636ef0d7f>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
.
<http://www.assero.co.uk/IC#164e72af-dd7b-433c-884f-21e95371936a>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#e934d7c6-2b70-4bd5-bee4-f3afcc4aaf2c>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
.
<http://www.assero.co.uk/IC#06123ac1-35d5-4e0e-b4d1-b0a6388f59a5>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
.
<http://www.assero.co.uk/IC#bed9d35e-8c26-40d3-9e82-a3b32b77bfe6>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
.
<http://www.assero.co.uk/IC#f3abf627-46d2-4d97-a068-b15333ce6b80>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
.
<http://www.assero.co.uk/IC#5da062ff-bff6-4e51-bb1e-82286307c9ef>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#11450f18-fd9e-4203-bf60-05c2fdedf3b6>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
.
<http://www.assero.co.uk/STA#92589d31-6e92-4331-be63-96b8b7b8c7db>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STA#4e32d2e9-b8a4-4ab2-acb7-eb06cbb687d9>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STFRM#f9a08469-2804-4ecd-a7f8-07a7cca1ada3>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#4e18dc0a-1a4d-4dff-842c-f3a88badcb57>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#56336c99-3c13-44d7-a17a-c62b35ca0ee8>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#68542f4f-68e4-4f01-a8d9-df94b88095a1>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#ccc6be6a-0346-4ea4-a82f-9e30fc9f996a>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#a13340e0-2c41-48f4-b3ff-45d649fc896a>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#81419f1a-ac1c-41a3-b37f-382f703f3492>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#b1d43f19-841f-43a9-8b90-a63d5d1963dd>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#6eafcf3a-2d16-4ab3-b3bc-1c55f60ff9b3>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#20dc755b-7130-48e3-9aee-f8865f2fc010>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#563ba7f6-f119-45e9-a63f-042223102765>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.
<http://www.assero.co.uk/STFRM#fe8fc631-1b01-439e-91c9-c671926e9fd9>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.